Italian drugmaker Recordati reported first-quarter 2026 revenue of 713 million euros ($775 million) on Tuesday, up 5% year-on ...

US biotech Rigel Pharmaceuticals is betting heavily on the newly-approved breast cancer therapy Veppanu (vepdegestrant), ...

A biotech company advancing next-generation targeted protein degradation (TPD) therapies for intractable diseases. Prazer Therapeutics was founded in 2019 and based in Seoul, South Korea. Its ...

Danish CNS specialist Lundbeck reported that total revenue for the first quarter of 2026 grew by +21% constant exchange rate ...

Privately-held Boston, USA, firm Cellular Intelligence has acquired global rights to Novo Nordisk's cell therapy program for ...

UK pharma major GSK has entered into an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group), through ...

The global DNA synthesis market is projected to grow from $5.7 billion in 2025 to $30.4 billion by 2035, according to a new ...

US biotech Inhibrx Biosciences (Nasdaq: INBX) has reported encouraging mid-stage data for its OX40 agonist INBRX-106, showing ...

US biotech MacroGenics (Nasdaq: MGNX) has agreed to sell its GMP manufacturing operations to Taiwanese contract manufacturer ...

Spanish drugmaker Almirall has reported first-quarter 2026 results in line with expectations, driven by continued strong ...

Drug regulators across major markets put safety, supply and post-market oversight at the centre of activity over the past ...

British drugmaker GSK (LSE: GSK) is paying up to $1 billion to partner with China’s Siran Biotechnology on an experimental ...